Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

M. Nowicka, LK. Hilton, M. Ashton-Key, CE. Hargreaves, C. Lee, R. Foxall, MJ. Carter, SA. Beers, KN. Potter, CR. Bolen, C. Klein, A. Knapp, F. Mir, M. Rose-Zerilli, C. Burton, W. Klapper, DW. Scott, LH. Sehn, U. Vitolo, M. Martelli, M. Trneny,...

. 2021 ; 5 (15) : 2945-2957. [pub] 20210810

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025139

Grantová podpora
C34999/A18087 Cancer Research UK - United Kingdom
ECMC C24563/A15581 Cancer Research UK - United Kingdom

Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and/or FcγRIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP/G-CHOP-treated patients in the GOYA trial (NCT01287741). In the discovery cohorts, higher FCGR2B expression was associated with significantly shorter progression-free survival (PFS; Arthur: hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.19; P = .0360; Schmitz: HR, 1.13; 95% CI, 1.02-1.26; P = .0243). Similar results were observed in GOYA with R-CHOP (HR, 1.26; 95% CI, 1.00-1.58; P = .0455), but not G-CHOP (HR, 0.91; 95% CI, 0.69-1.20; P = .50). A nonsignificant trend that high FCGR2B expression favored G-CHOP over R-CHOP was observed (HR, 0.67; 95% CI, 0.44-1.02; P = .0622); however, low FCGR2B expression favored R-CHOP (HR, 1.58; 95% CI, 1.00-2.50; P = .0503). In Arthur and GOYA, FCGR2B expression was associated with tumor FcγRIIB expression; correlating with shorter PFS for R-CHOP (HR, 2.17; 95% CI, 1.04-4.50; P = .0378), but not G-CHOP (HR, 1.37; 95% CI, 0.66-2.87; P = .3997). This effect was independent of established prognostic biomarkers. High FcγRIIB/FCGR2B expression has prognostic value in R-treated patients with DLBCL and may confer differential responsiveness to R-CHOP/G-CHOP.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025139
003      
CZ-PrNML
005      
20211026134104.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2021004770 $2 doi
035    __
$a (PubMed)34323958
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nowicka, Malgorzata $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
245    10
$a Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment / $c M. Nowicka, LK. Hilton, M. Ashton-Key, CE. Hargreaves, C. Lee, R. Foxall, MJ. Carter, SA. Beers, KN. Potter, CR. Bolen, C. Klein, A. Knapp, F. Mir, M. Rose-Zerilli, C. Burton, W. Klapper, DW. Scott, LH. Sehn, U. Vitolo, M. Martelli, M. Trneny, CK. Rushton, GW. Slack, P. Farinha, JC. Strefford, MZ. Oestergaard, RD. Morin, MS. Cragg
520    9_
$a Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and/or FcγRIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP/G-CHOP-treated patients in the GOYA trial (NCT01287741). In the discovery cohorts, higher FCGR2B expression was associated with significantly shorter progression-free survival (PFS; Arthur: hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.19; P = .0360; Schmitz: HR, 1.13; 95% CI, 1.02-1.26; P = .0243). Similar results were observed in GOYA with R-CHOP (HR, 1.26; 95% CI, 1.00-1.58; P = .0455), but not G-CHOP (HR, 0.91; 95% CI, 0.69-1.20; P = .50). A nonsignificant trend that high FCGR2B expression favored G-CHOP over R-CHOP was observed (HR, 0.67; 95% CI, 0.44-1.02; P = .0622); however, low FCGR2B expression favored R-CHOP (HR, 1.58; 95% CI, 1.00-2.50; P = .0503). In Arthur and GOYA, FCGR2B expression was associated with tumor FcγRIIB expression; correlating with shorter PFS for R-CHOP (HR, 2.17; 95% CI, 1.04-4.50; P = .0378), but not G-CHOP (HR, 1.37; 95% CI, 0.66-2.87; P = .3997). This effect was independent of established prognostic biomarkers. High FcγRIIB/FCGR2B expression has prognostic value in R-treated patients with DLBCL and may confer differential responsiveness to R-CHOP/G-CHOP.
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a lidé $7 D006801
650    12
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x genetika $7 D016403
650    _2
$a prognóza $7 D011379
650    _2
$a receptory IgG $x genetika $7 D017452
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a vinkristin $x terapeutické užití $7 D014750
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hilton, Laura K $u BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada $u Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada
700    1_
$a Ashton-Key, Margaret $u School of Cancer Sciences, University of Southampton, Southampton, United Kingdom $u Southampton University Hospitals NHS Foundation Trust, Southampton, United Kingdom
700    1_
$a Hargreaves, Chantal E $u School of Cancer Sciences, University of Southampton, Southampton, United Kingdom
700    1_
$a Lee, Chern $u Southampton University Hospitals NHS Foundation Trust, Southampton, United Kingdom
700    1_
$a Foxall, Russell $u Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom
700    1_
$a Carter, Matthew J $u Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom
700    1_
$a Beers, Stephen A $u Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom
700    1_
$a Potter, Kathleen N $u School of Cancer Sciences, University of Southampton, Southampton, United Kingdom
700    1_
$a Bolen, Christopher R $u Genentech, Inc., South San Francisco, CA
700    1_
$a Klein, Christian $u Roche Innovation Center Zurich, Schlieren, Switzerland
700    1_
$a Knapp, Andrea $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Mir, Farheen $u Royal Marsden Hospital, Sutton, United Kingdom
700    1_
$a Rose-Zerilli, Matthew $u School of Cancer Sciences, University of Southampton, Southampton, United Kingdom
700    1_
$a Burton, Cathy $u St James's Institute of Oncology, Leeds, United Kingdom
700    1_
$a Klapper, Wolfram $u Department of Hematopathology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Scott, David W $u BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada $u Department of Medicine, University of British Columbia, Vancouver, BC, Canada
700    1_
$a Sehn, Laurie H $u BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada $u Department of Medicine, University of British Columbia, Vancouver, BC, Canada
700    1_
$a Vitolo, Umberto $u Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
700    1_
$a Martelli, Maurizio $u Department of Translational and Precision Medicine, Hematology, Sapienza University, Rome, Italy
700    1_
$a Trneny, Marek $u 1st Medical Faculty, Charles University, Prague, Czech Republic; and
700    1_
$a Rushton, Christopher K $u Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada; and
700    1_
$a Slack, Graham W $u BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada
700    1_
$a Farinha, Pedro $u BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada
700    1_
$a Strefford, Jonathan C $u School of Cancer Sciences, University of Southampton, Southampton, United Kingdom
700    1_
$a Oestergaard, Mikkel Z $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Morin, Ryan D $u Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada $u Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada; and
700    1_
$a Cragg, Mark S $u School of Cancer Sciences, University of Southampton, Southampton, United Kingdom $u Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 5, č. 15 (2021), s. 2945-2957
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34323958 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134110 $b ABA008
999    __
$a ok $b bmc $g 1714267 $s 1145646
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 5 $c 15 $d 2945-2957 $e 20210810 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
GRA    __
$a C34999/A18087 $p Cancer Research UK $2 United Kingdom
GRA    __
$a ECMC C24563/A15581 $p Cancer Research UK $2 United Kingdom
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace